Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cel-Sci Corporation stock logo
CVM
Cel-Sci
$10.11
+2.4%
$9.61
$1.98
$32.70
$67.93M0.52115,747 shs37,383 shs
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
$23.01
$22.89
$3.11
$23.21
$389.61M2.111.52 million shsN/A
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$8.14
+2.6%
$7.86
$4.55
$8.98
$637.95M1.34397,952 shs264,296 shs
Orchard Therapeutics plc stock logo
ORTX
Orchard Therapeutics
$16.70
$16.59
$4.24
$16.72
$380.09M0.55157,287 shsN/A
Poseida Therapeutics, Inc. stock logo
PSTX
Poseida Therapeutics
$9.50
$9.48
$2.32
$9.67
$928.85M1.631.12 million shsN/A
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cel-Sci Corporation stock logo
CVM
Cel-Sci
+2.43%+0.80%+2.43%+142.45%-64.68%
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
0.00%0.00%0.00%0.00%0.00%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
+2.65%-1.45%+11.05%-5.57%+52.72%
Orchard Therapeutics plc stock logo
ORTX
Orchard Therapeutics
0.00%0.00%0.00%0.00%0.00%
Poseida Therapeutics, Inc. stock logo
PSTX
Poseida Therapeutics
0.00%0.00%0.00%0.00%+274.02%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cel-Sci Corporation stock logo
CVM
Cel-Sci
$10.11
+2.4%
$9.61
$1.98
$32.70
$67.93M0.52115,747 shs37,383 shs
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
$23.01
$22.89
$3.11
$23.21
$389.61M2.111.52 million shsN/A
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$8.14
+2.6%
$7.86
$4.55
$8.98
$637.95M1.34397,952 shs264,296 shs
Orchard Therapeutics plc stock logo
ORTX
Orchard Therapeutics
$16.70
$16.59
$4.24
$16.72
$380.09M0.55157,287 shsN/A
Poseida Therapeutics, Inc. stock logo
PSTX
Poseida Therapeutics
$9.50
$9.48
$2.32
$9.67
$928.85M1.631.12 million shsN/A
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cel-Sci Corporation stock logo
CVM
Cel-Sci
+2.43%+0.80%+2.43%+142.45%-64.68%
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
0.00%0.00%0.00%0.00%0.00%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
+2.65%-1.45%+11.05%-5.57%+52.72%
Orchard Therapeutics plc stock logo
ORTX
Orchard Therapeutics
0.00%0.00%0.00%0.00%0.00%
Poseida Therapeutics, Inc. stock logo
PSTX
Poseida Therapeutics
0.00%0.00%0.00%0.00%+274.02%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cel-Sci Corporation stock logo
CVM
Cel-Sci
0.00
N/AN/AN/A
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
0.00
N/AN/AN/A
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
2.33
Hold$24.00194.84% Upside
Orchard Therapeutics plc stock logo
ORTX
Orchard Therapeutics
0.00
N/AN/AN/A
Poseida Therapeutics, Inc. stock logo
PSTX
Poseida Therapeutics
2.00
Hold$9.50N/A

Current Analyst Ratings Breakdown

Latest MGTX, PSTX, ORTX, CVM, and HARP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/8/2025
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/27/2025
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
8/15/2025
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$35.00
(Data available from 10/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cel-Sci Corporation stock logo
CVM
Cel-Sci
N/AN/AN/AN/A$6.06 per shareN/A
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
$37.34M10.43N/AN/A$1.63 per share14.12
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$33.28M19.68N/AN/A$0.87 per share9.36
Orchard Therapeutics plc stock logo
ORTX
Orchard Therapeutics
$22.66M16.77N/AN/A$7.74 per share2.16
Poseida Therapeutics, Inc. stock logo
PSTX
Poseida Therapeutics
$150.86M6.16N/AN/A$1.08 per share8.80
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cel-Sci Corporation stock logo
CVM
Cel-Sci
-$26.92M-$9.77N/AN/AN/AN/A-259.38%-107.21%N/A
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
-$67.73M-$8.76N/AN/AN/A-81.68%-893.55%-45.98%N/A
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-$147.79M-$2.04N/A21.42N/A-415.39%-314.44%-63.28%11/12/2025 (Estimated)
Orchard Therapeutics plc stock logo
ORTX
Orchard Therapeutics
-$150.66M-$0.94N/AN/AN/A-333.90%-74.94%-33.51%N/A
Poseida Therapeutics, Inc. stock logo
PSTX
Poseida Therapeutics
-$123.43M-$0.63N/AN/AN/A-40.28%-72.26%-21.53%N/A

Latest MGTX, PSTX, ORTX, CVM, and HARP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/12/2025Q3 2025
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-$0.51N/AN/AN/A$7.71 millionN/A
8/14/2025Q2 2025
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-$0.52-$0.48+$0.04-$0.48$8.00 million$3.69 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cel-Sci Corporation stock logo
CVM
Cel-Sci
N/AN/AN/AN/AN/A
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
N/AN/AN/AN/AN/A
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
N/AN/AN/AN/AN/A
Orchard Therapeutics plc stock logo
ORTX
Orchard Therapeutics
N/AN/AN/AN/AN/A
Poseida Therapeutics, Inc. stock logo
PSTX
Poseida Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cel-Sci Corporation stock logo
CVM
Cel-Sci
0.89
0.47
0.37
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
N/A
1.89
1.89
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
26.29
0.88
0.88
Orchard Therapeutics plc stock logo
ORTX
Orchard Therapeutics
0.20
3.12
2.98
Poseida Therapeutics, Inc. stock logo
PSTX
Poseida Therapeutics
0.68
3.20
3.20

Institutional Ownership

CompanyInstitutional Ownership
Cel-Sci Corporation stock logo
CVM
Cel-Sci
12.08%
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
74.01%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
67.48%
Orchard Therapeutics plc stock logo
ORTX
Orchard Therapeutics
29.90%
Poseida Therapeutics, Inc. stock logo
PSTX
Poseida Therapeutics
46.87%

Insider Ownership

CompanyInsider Ownership
Cel-Sci Corporation stock logo
CVM
Cel-Sci
9.93%
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
17.00%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
7.50%
Orchard Therapeutics plc stock logo
ORTX
Orchard Therapeutics
2.91%
Poseida Therapeutics, Inc. stock logo
PSTX
Poseida Therapeutics
2.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cel-Sci Corporation stock logo
CVM
Cel-Sci
436.88 million6.20 millionOptionable
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
5316.93 million14.05 millionOptionable
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
30080.45 million74.41 millionOptionable
Orchard Therapeutics plc stock logo
ORTX
Orchard Therapeutics
16622.76 million22.10 millionOptionable
Poseida Therapeutics, Inc. stock logo
PSTX
Poseida Therapeutics
26097.77 million94.94 millionOptionable

Recent News About These Companies

Roche set to finalise $1.5bn Poseida Therapeutics takeover
Poseida Therapeutics downgraded to Neutral from Overweight at Piper Sandler
The PSTX Stock Mystery: Why Did PSTX Plunge Today?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cel-Sci stock logo

Cel-Sci NYSEAMERICAN:CVM

$10.11 +0.24 (+2.43%)
Closing price 10/15/2025 04:10 PM Eastern
Extended Trading
$10.02 -0.08 (-0.84%)
As of 04:17 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

Harpoon Therapeutics stock logo

Harpoon Therapeutics NASDAQ:HARP

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California. As of March 11, 2024, Harpoon Therapeutics, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.

MeiraGTx stock logo

MeiraGTx NASDAQ:MGTX

$8.14 +0.21 (+2.65%)
Closing price 10/15/2025 04:00 PM Eastern
Extended Trading
$8.16 +0.02 (+0.31%)
As of 10/15/2025 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

Orchard Therapeutics stock logo

Orchard Therapeutics NASDAQ:ORTX

Orchard Therapeutics, a Kyowa Kirin company, is a global gene therapy leader focused on ending the devastation caused by genetic and other severe diseases by discovering, developing, and commercializing new treatments that tap into the curative potential of hematopoietic stem cell (HSC) gene therapy. In this approach, a patient’s own blood stem cells are genetically modified outside of the body and then reinserted, with the goal of correcting the underlying cause of disease with a single treatment. Founded in 2015, Orchard’s roots go back to some of the first research and clinical developments involving HSC gene therapy. Our team has played a central role in the evolution of this technology from a promising scientific idea to a potentially life-transforming reality. Today, Orchard is advancing a pipeline of HSC gene therapies designed to address serious diseases where the burden is immense for patients, families and society and current treatment options are limited or do not exist.

Poseida Therapeutics stock logo

Poseida Therapeutics NASDAQ:PSTX

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC. In addition, the company engages in the development of P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; P-OTC-101, a clinical stage liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; and P-PAH-101, a clinical stage liver-directed gene therapy for the in vivo treatment of phenylketonuria. It has a research collaboration and license agreement with F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.